Lifecore Biomedical (NASDAQ:LFCR) Releases Earnings Results, Beats Estimates By $0.01 EPS

Lifecore Biomedical (NASDAQ:LFCR) posted its quarterly earnings data on Wednesday. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01, FiscalAI reports. The business had revenue of $34.17 million during the quarter, compared to the consensus estimate of $32.02 million.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• Reaffirmed 2026 guidance for revenue of $120 million–$125 million and adjusted EBITDA of $20.5 million–$25 million, with stronger CDMO revenue expected in the second half, particularly in Q4.
• Contractually committed fill-finish demand from Lifecore’s largest customer is expected to double in 2027 and increase more than 200% in 2028 versus 2026, while a successful PMDA inspection supports potential expansion into Japan.
• The company added six pipeline programs during the quarter and nine year-to-date, including late-stage and commercial site-transfer opportunities; management believes 11 existing development programs could commercialize by the end of 2028.
• Second-quarter revenue fell 6.2% to $34.2 million, while six-month revenue declined 19.9% to $57.4 million; adjusted EBITDA decreased to $8.6 million in the quarter and $9.6 million for the six-month period, and the quarterly net loss widened to $6.2 million.
• Liquidity improved to approximately $38.8 million, but potential Series A preferred payments are not due until December 2028 and would require lender approval; unpaid amounts would accrue interest at 1% per month.

Lifecore Biomedical Price Performance

Lifecore Biomedical stock opened at $4.44 on Thursday. The business has a 50 day simple moving average of $5.03 and a 200 day simple moving average of $5.60. The company has a market capitalization of $166.54 million, a PE ratio of -4.72 and a beta of 1.08. Lifecore Biomedical has a one year low of $3.63 and a one year high of $8.98.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of LFCR. Quarry LP acquired a new stake in shares of Lifecore Biomedical in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets grew its holdings in shares of Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock worth $43,000 after purchasing an additional 2,786 shares during the last quarter. State of Wyoming acquired a new stake in shares of Lifecore Biomedical during the 2nd quarter worth about $69,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Lifecore Biomedical during the 2nd quarter worth about $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Lifecore Biomedical by 14.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after purchasing an additional 1,886 shares during the last quarter. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Zacks Research raised shares of Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Wall Street Zen raised shares of Lifecore Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Barrington Research raised their price target on shares of Lifecore Biomedical from $6.00 to $6.50 and gave the stock an “outperform” rating in a research report on Tuesday, June 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Lifecore Biomedical in a report on Tuesday. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Lifecore Biomedical presently has a consensus rating of “Hold” and an average target price of $6.50.

Lifecore Biomedical News Summary

Here are the key news stories impacting Lifecore Biomedical this week:

• Positive Sentiment: Q2 results exceeded expectations. Lifecore reported a loss of $0.19 per share, narrower than the $0.22 consensus loss, while revenue reached $34.17 million versus expectations of $32.02 million. Lifecore Biomedical second-quarter results
• Positive Sentiment: Management reaffirmed its fiscal 2026 outlook, including revenue of $120 million to $125 million, broadly consistent with the $122 million analyst consensus. The company also cited multiple new business wins that expand its development and manufacturing pipeline. Lifecore reaffirms 2026 guidance
• Positive Sentiment: The longer-term demand outlook was encouraging. Lifecore indicated that fill-and-finish demand could double in 2027 and grow more than 200% in 2028, potentially improving capacity utilization and future revenue visibility. Ongoing cost-reduction and productivity initiatives may also support margins.
• Neutral Sentiment: The earnings beat was constructive but modest, and the full-year revenue forecast was essentially in line with expectations rather than an upgrade. Investors are likely to focus on whether recently won programs convert into revenue on schedule.
• Negative Sentiment: Lifecore remains unprofitable, with analysts expecting a full-year loss, so the company’s valuation and stock performance continue to depend on executing its growth pipeline, improving costs, and reaching sustainable profitability. Lifecore Q2 2026 earnings call transcript

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.